We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
CAVADEXA , ABADINE, ABALAMID HETERO , BACAMID, LAMAVIR 600/300 (Hetero Australia Pty Ltd)
Product name
CAVADEXA , ABADINE, ABALAMID HETERO , BACAMID, LAMAVIR 600/300
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
197 (255 working days)
Active ingredients
Lamivudine, Abacavir sulfate
Registration type
New generic medicine
Indication
CAVADEXA, ABADINE, ABALAMID HETERO , BACAMID, LAMAVIR 600/300 tablets are a combination of two nucleoside analogues (abacavir and lamivudine).
CAVADEXA, ABADINE, ABALAMID HETERO , BACAMID, LAMAVIR 600/300 is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection in adults and adolescents from 12 years of age.